Greenland Mines Ltd. (NASDAQ: GRML) has announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This development is significant as it strengthens Greenland Mines’ position in the competitive biotech landscape, particularly for therapies addressing neurodegenerative conditions that affect millions worldwide. The patent protection in Canada could facilitate future clinical trials and commercial partnerships in the region.
Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The advancement of KLTO-202 to GMP manufacturing marks a critical milestone, indicating readiness for potential clinical trials. For investors and the industry, this progress suggests that the company is moving closer to bringing a novel therapy to market, which could have substantial implications for ALS patients and other neurodegenerative disease sufferers.
The patent grant also reinforces the company’s dual operating divisions: mining and biotech. While the mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project, the biotech division is advancing Klotho-based therapies. This diversification strategy may appeal to investors seeking exposure to both critical minerals and biotechnology.
For the broader industry, the patent underscores the growing interest in Klotho as a therapeutic target. Klotho is known for its anti-aging properties and potential to enhance cognitive function. If successful, Greenland Mines’ therapies could transform treatment paradigms for neurodegenerative diseases, which currently have limited options. The company’s progress may also spur further research and investment into gene therapies targeting similar pathways.
For more information, the full press release is available at https://ibn.fm/x2pHA. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
